Furthermore, studies have shown that increased MCP-1 expression in T2D patients correlates with higher HOMA-IR values, reduced insulin sensitivity, and deteriorating glycaemic control, suggesting its potential as both a biomarker and therapeutic target in managing insulin resistance and inflammation in T2D [82]. Here, CCL2 is linked to Insulin resistance.